flutamide has been researched along with Urination Disorders in 8 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Five hundred forty-six patients with advanced loco-regional (M0) or distant metastatic (M1) prostatic carcinoma treated with flutamide combined with either orchiectomy or LHRH analogues were included in this analysis." | 5.08 | PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients. ( Casselman, J; Derde, MP; Kaufman, L; Mattelaer, J; Oosterlinck, W; Van Velthoven, R, 1997) |
| "Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy." | 2.65 | Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy. ( Sogani, PC; Vagaiwala, MR; Whitmore, WF, 1984) |
| " This technique has been used most commonly to treat prostate cancers in combination with hormonal therapy." | 2.42 | Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men. ( Igaki, H; Kaizu, T; Karasawa, K; Matsuda, T; Niibe, Y; Shinohara, M; Tanaka, Y, 2003) |
| "We collected the data of 45 advanced prostate cancer patients complicated with lower urinary tract symptoms who were treated by MAB." | 1.37 | [Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade]. ( Gui, M; He, L; Li, W; Long, Z; Zhong, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rodda, S | 1 |
| Morris, WJ | 1 |
| Hamm, J | 1 |
| Duncan, G | 1 |
| Zhong, K | 1 |
| Li, W | 1 |
| Gui, M | 1 |
| Long, Z | 1 |
| He, L | 1 |
| Karasawa, K | 1 |
| Kaizu, T | 1 |
| Niibe, Y | 1 |
| Igaki, H | 1 |
| Shinohara, M | 1 |
| Tanaka, Y | 1 |
| Matsuda, T | 1 |
| Sogani, PC | 1 |
| Vagaiwala, MR | 1 |
| Whitmore, WF | 1 |
| da Silva, FC | 1 |
| Oosterlinck, W | 1 |
| Mattelaer, J | 1 |
| Casselman, J | 1 |
| Van Velthoven, R | 1 |
| Derde, MP | 1 |
| Kaufman, L | 1 |
| Bonard, M | 1 |
| de Almeida, S | 1 |
| von Niederhäusern, W | 1 |
| Stone, NN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Study Comparing Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by High Dose 3-D Conformal Boost Versus Androgen Suppression and Elective Pelvic Nodal Irradiation Followed by 125-Iodine Brachytherapy Implant Boos[NCT00175396] | Phase 3 | 400 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flutamide and Urination Disorders
| Article | Year |
|---|---|
Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Ch | 2003 |
6 trials available for flutamide and Urination Disorders
| Article | Year |
|---|---|
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Ho | 2017 |
Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.
Topics: Acid Phosphatase; Adenocarcinoma; Adult; Aged; Anilides; Bone Neoplasms; Clinical Trials as Topic; F | 1984 |
Quality of life in prostatic carcinoma.
Topics: Activities of Daily Living; Flutamide; Goserelin; Humans; Interpersonal Relations; Male; Orchiectomy | 1993 |
PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Topics: Aged; Analysis of Variance; Androgen Antagonists; Antineoplastic Agents, Hormonal; Belgium; Carcinom | 1997 |
Placebo-controlled double-blind study in human benign obstructive prostatic hypertrophy with flutamide.
Topics: Anilides; Clinical Trials as Topic; Flutamide; Humans; Male; Middle Aged; Organ Size; Placebos; Pros | 1976 |
Flutamide in treatment of benign prostatic hypertrophy.
Topics: Anilides; Double-Blind Method; Flutamide; Humans; Male; Multicenter Studies as Topic; Prostatic Hype | 1989 |
1 other study available for flutamide and Urination Disorders
| Article | Year |
|---|---|
[Improvement of lower urinary tract symptoms in patients with prostate cancer treated with maximal androgen blockade].
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Flutamide; Humans; Male; Middle Aged; Neopl | 2011 |